# Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

> **NCT02525939** · PHASE3 · COMPLETED · sponsor: **DalCor Pharmaceuticals** · enrollment: 6147 (actual)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** dalcetrapib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02525939
- **Lead sponsor:** DalCor Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2021-10
- **Final completion:** 2021-10
- **Target enrollment:** 6147 (ACTUAL)
- **Last updated:** 2022-10-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02525939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02525939, "Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT02525939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*